For many years, we have manufactured and sold a variety of pharmaceutical products, such as antidepressants widely used in the medical field, Choreazine, a treatment agent for chorea associated with Huntington's disease which caught the orphan drug designation, and anti-allergic agents that demonstrate superior clinical efficacy in treating allergic symptoms such as urticaria and bronchial asthma. We also have a therapeutic drug which accelerates the metabolism of triglycerides for the treatment of liver diseases. In addition, we are actively working to create new drugs, including Midafresa, an anticonvulsant launched in December 2014 as a new option for treating status epilepticus; and Sabril, an antiepilepsy drug that hit markets in July 2016.

We are promoting initiatives for the domestic launch of drugs that have been approved abroad for treatment of hitherto untreatable diseases and diseases where treatment satisfaction is low. One of these is Modiodal, a sleep disorder treatment drug.
Modiodal has already been approved and is sold in many countries worldwide. Alfresa Pharma was the first company in Japan to obtain manufacturing and marketing approval of Modiodal in January 2007 for the treatment of the excessive daytime sleepiness associated with narcolepsy. This pharmaceutical product is currently also prescribed for sleep apnea syndrome (approved in November 2011) and idiopathic hypersomnia (approved in February 2020), and is contributing to increased quality-of-life for patients.